Gastroenterology
Volume 138, Issue 3 , Pages 896-904 , March 2010

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

  • Laura E. Targownik

      Affiliations

    • Section of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • Corresponding Author InformationReprint requests Address requests for reprints to: Laura Targownik, MD, MSHS, 805G-715 McDermot Avenue, Winnipeg, Manitoba, Canada R3N 0V6
    • ,
  • Lisa M. Lix

      Affiliations

    • School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    • ,
  • Stella Leung

      Affiliations

    • Section of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • ,
  • William D. Leslie

      Affiliations

    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • Section of Nuclear Medicine, Department of Radiology, University of Manitoba, Winnipeg, Manitoba, Canada
    • Section of Endocrinology & Metabolism, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Received 17 March 2009 ,Accepted 12 November 2009.

References 

  1. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768
  2. Hannan EL, Magaziner J, Wang JJ, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA. 2001;285:2736–2742
  3. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women (The study of osteoporotic fractures). Arch Intern Med. 1996;156:1521–1525
  4. Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int. 2004;15:834–841
  5. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women (Study of Osteoporotic Fractures Research Group). N Engl J Med. 1995;332:767–773
  6. Ensrud KE, Cauley J, Lipschutz R, Cummings SR. Weight change and fractures in older women (Study of Osteoporotic Fractures Research Group). Arch Intern Med. 1997;157:857–863
  7. Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women (Study of Osteoporotic Fractures Research Group). Ann Intern Med. 1998;129:81–88
  8. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000
  9. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–1251
  10. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–326
  11. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953
  12. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83
  13. Roos NP. Establishing a population data-based policy unit. Med Care. 1999;37:JS15–JS26
  14. Roos NP, Shapiro E. Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care. 1999;37:JS10–JS14
  15. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102:942–950
  16. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–944
  17. Leslie WD, Anderson WA, Metge CJ, Manness LJ. Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study. Bone. 2007;40:991–996
  18. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease (A population-based cohort study). Ann Intern Med. 2000;133:795–799
  19. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42:467–475
  20. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7–29, 2000. highlights of the conference. South Med J. 2001;94:569–573
  21. Leslie WD, Caetano PA, MacWilliam LR, Finlayson GS. Construction and validation of a population-based bone densitometry database. J Clin Densitom. 2005;8:25–30
  22. Leslie WD. The importance of spectrum bias on bone density monitoring in clinical practice. Bone. 2006;39:361–368
  23. Corley DA. Proton pump inhibitors, H2 antagonists, and risk of hip fracture: a large population-based study. Gastroenterology. 2009;136:A70
  24. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951–959
  25. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–259
  26. Gueguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr. 2000;19(suppl):119S–136S
  27. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73:640–647
  28. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–73
  29. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev. 2008;66:103–108
  30. Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001;36:1011–1015
  31. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841
  32. Gagnemo-Persson R, Hakanson R, Sundler F, Persson P. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol. 1994;29:493–497
  33. Grimelius L, Johansson H, Lundqvist G, Olazabal A, Polak JH, Pearse GE. The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol. 1977;12:739–744
  34. Marcinowska-Suchowierska EB, Talalaj MJ, Wlodarcyzk AW, Bielecki K, Zawadzki JJ, Brzozowski R. Calcium/phosphate/vitamin D homeostasis and bone mass in patients after gastrectomy, vagotomy, and cholecystectomy. World J Surg. 1995;19:597–602
  35. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–1954
  36. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–2793
  37. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202
  38. Beck TJ, Ruff CB, Warden KE, Scott WW, Rao GU. Predicting femoral neck strength from bone mineral data (A structural approach). Invest Radiol. 1990;25:6–18
  39. Genant HK, Engelke K, Prevrhal S. Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford). 2008;47(Suppl 4):iv, 9–16
  40. Bouxsein ML. Technology insight: noninvasive assessment of bone strength in osteoporosis. Nat Clin Pract Rheumatol. 2008;4:310–318
  41. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008;476:33–42
  42. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop. 2003;32:222–228
  43. Leslie WD, Tsang JF, Lix LM. Validation of ten-year fracture risk prediction: A clinical cohort study from the Manitoba Bone Density Program. Bone. 2008;43:667–671

 Conflicts of interest The authors disclose the following: Dr Laura Targownik has served on advisory boards for Janssen-Ortho Canada and Astra-Zeneca Canada and on the speaker's bureau for Astra-Zeneca Canada. Both companies either currently or at one time marketed particular proton pump inhibitors in Canada. The remaining authors disclose no conflicts.

 Funding Dr Targownik is supported by a Canadian Institutes of Health Research New Investigator Grant in Osteoporosis, and by Osteoporosis Canada. Dr Leslie is supported by the Canadian Institutes of Health Research. Dr Lix is supported by a CIHR New Investigator Award. This project was funded by a grant from the Canadian Institutes of Health Research Regional Partnership Program and the Manitoba Health Research Council.

PII: S0016-5085(09)02030-7

doi: 10.1053/j.gastro.2009.11.014

Gastroenterology
Volume 138, Issue 3 , Pages 896-904 , March 2010

Article Tools